Equity Overview
Price & Market Data
Price: $0.0195
Daily Change: -$0.00155 / 7.95%
Range: $0.0195 - $0.021
Market Cap: $2,388,940
Volume: 82,500
Performance Metrics
1 Week: 1.82%
1 Month: -15.28%
3 Months: 14.29%
6 Months: -21.95%
1 Year: -10.76%
YTD: -20.00%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.